Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of claims:

Claim 1. (Currently amended) A pharmaceutical composition for topical administration, said composition consisting of:

at least 5% by weight, based on the total weight of the composition, of minoxidil or a pharmaceutically acceptable minoxidil salt selected from the group consisting of minoxidil acetate, minoxidil citrate, minoxidil succinate, minoxidil benzoate, minoxidil hydrochloride, minoxidil sulphate, minoxidil phosphate, and minoxidil lactate, as sole hair-growing active present in the composition, and wherein the minoxidil or salt thereof is not encapsulated:

an acid in an amount to substantially completely solubilize the minoxidil or the pharmaceutically acceptable minoxidil salt;

a solvent of water and a lower alcohol wherein the ratio of water to alcohol is in a range of approximately 9:1 to 1:9 by volume;

a co-solvent selected from one or more of the group consisting of aromatic alcohols and polyhydric alcohols, wherein when the co-solvent comprises propylene glycol, the propylene glycol is present in an amount of less than $\frac{5\%}{10\%}$ [[10%]] by weight;

optionally one or more penetration agents selected from the group consisting of dodecanol, oleyl alcohol, an amine, a carboxylic acid, an ester, azone, N-methyl pyrollidone, a bile salt, urea, and mixtures thereof; and

optionally one or more excipients selected from the group consisting of a higher alcohol, a vitamin, a preservative, a buffer, a stabilizer, a hair generating agent, an antibacterial agent, a refrigerant, an amino acid, a perfume, an antioxidant, a UV absorber, a dye, a humectant, a thickener, a gelling agent, and a color additive,

wherein the apparent pH of the final product is in the range of from approximately 5.0 to 7.0, and wherein the pharmaceutical composition upon actuation with a propellant forms a foam or mousse.

Claim 2. (Cancelled)

Claim 3. (Previously presented) The pharmaceutical composition according to claim 1, wherein the minoxidil or the pharmaceutically acceptable minoxidil salt is present in an amount of from at least 5 to 25% by weight, based on the total weight of the pharmaceutical composition.

Claim 4. (Previously presented) The pharmaceutical composition according to claim 3, wherein the minoxidil or the pharmaceutically acceptable minoxidil salt is present in an amount of from 7.5 to 12% by weight, based on the total weight of the

Application No. 09/673,872 Attorney Docket No. C7979U Page 4 of 22

pharmaceutical composition.

Claims 5-7. (Cancelled)

Claim 8. (Previously presented) The pharmaceutical composition according to claim 1, wherein the acid is acetic acid or lactic acid.

Claim 9-11. (Cancelled)

Claim 12. (Previously presented) The pharmaceutical composition according to claim 1, wherein the water is present in an amount no greater than approximately 60% by weight based on the total weight of the composition.

Claim 13. (Previously presented) The pharmaceutical composition according to claim 1, wherein the co-solvent is an alkylene glycol.

Claim 14. (Previously presented) The pharmaceutical composition according to claim 13, wherein the alkylene glycol is selected from one or more of the group consisting of glycerol, 1,3-butylene glycol and propylene glycol.

Claim 15. (Previously presented) The pharmaceutical composition according to claim

Application No. 09/673,872 Attorney Docket No. C7979U Page 5 of 22

1, wherein the acid is present at a level that provides at least 0.01 Normal acid.

Claim 16. (Previously presented) The pharmaceutical composition according to claim 1, wherein the acid is present in an amount equal to or greater than the amount of the minoxidil in Normal amounts

Claims 17-18. (Canceled)

Claim 19. (Previously presented) The pharmaceutical composition according to claim 1, wherein the minoxidil salt is minoxidil acetate or minoxidil lactate.

Claim 20. (Canceled)

Claim 21. (Currently amended) A method for the treatment of hair loss and related indications in humans, comprising the steps of:

providing a pharmaceutical composition, consisting of

at least 5% by weight, based on the total weight of the composition, of minoxidil or a pharmaceutically acceptable minoxidil salt selected from the group consisting of minoxidil acetate, minoxidil citrate, minoxidil succinate, minoxidil benzoate, minoxidil hydrochloride, minoxidil sulphate, minoxidil phosphate, and minoxidil

lactate, as sole hair-growing active present in the composition, and wherein the minoxidil or salt thereof is not encapsulated:

an acid in an amount to substantially completely solubilize the minoxidil or the pharmaceutically acceptable minoxidil salt;

a solvent of water and a lower alcohol wherein the ratio of water to alcohol is in a range of approximately 9:1 to 1:9 by volume;

a co-solvent selected from one or more of the group consisting of aromatic alcohols and polyhydric alcohols, wherein when the co-solvent comprises propylene glycol, the propylene glycol is present in an amount of less than 5% [[10%]] by weight:

optionally one or more penetration agents selected from the group consisting of dodecanol, oleyl alcohol, an amine, a carboxylic acid, an ester, azone, N-methyl pyrollidone, a bile salt, urea, and mixtures thereof; and

optionally one or more excipients selected from the group consisting of a higher alcohol, a vitamin, a preservative, a buffer, a stabilizer, a hair generating agent, an antibacterial agent, a refrigerant, an amino acid, a perfume, an antioxidant, a UV absorber, a dye, a humectant, a thickener, a gelling agent, and a color additive, and wherein the apparent pH of the final product is in the range of from approximately 5.0 to 7.0,

Application No. 09/673,872 Attorney Docket No. C7979U

Page 7 of 22

actuating the pharmaceutical composition with a propellant to form the

pharmaceutical composition as a foam or mousse; and

applying topically to the human scalp a therapeutically effective amount of the

foam or mousse.

Claim 22. (Cancelled)

Claim 23. (Previously presented) The method according to claim 21, wherein the

minoxidil salt is minoxidil acetate or minoxidil lactate.

Claim 24. (Previously presented) The method according to claim 21, wherein the

minoxidil or the pharmaceutically acceptable minoxidil salt is present in an amount of

from at least 5 to 25% by weight, based on the total weight of the composition.

Claim 25. (Cancelled)

 ${\it Claim 26.} \ (Previously\ presented)\ The\ pharmaceutical\ composition\ according\ to\ claim$

1, wherein the lower alcohol is ethanol.

Claims 27-28. (Cancelled)

Claim 29. (Previously presented) The pharmaceutical composition according to claim

Application No. 09/673,872 Attorney Docket No. C7979U

Page 8 of 22

26, wherein the ratio of water to ethanol is approximately 1:1 to 1:3 by volume.

Claims 30.-138. (Canceled)

Claim 139. (Previously presented) The pharmaceutical composition according to claim

8, wherein the acid is lactic acid.

Claim 140. (Previously presented) The pharmaceutical composition according to claim

14, wherein the alkylene glycol is glycerol.

Claim 141. (Previously presented) The pharmaceutical composition according to claim

1, wherein the higher alcohol is present in the pharmaceutical composition and is

selected from the group consisting of cetyl alcohol, stearyl alcohol, and combinations

thereof.

Claim 142. (Previously presented) The pharmaceutical composition according to claim

1, wherein the stabilizer is present in the pharmaceutical composition and is

Polysorbate 60.

Claim 143. (Previously presented) The pharmaceutical composition according to claim

1, wherein the propellant is selected from the group consisting of one or more

hydrocarbons, dimethyl ether, and a chlorofluorocarbon.

Claim 144. (Previously presented) The pharmaceutical composition according to claim 143, wherein the propellant is one or more hydrocarbons.

Claim 145. (Previously presented) The pharmaceutical composition according to claim 1, wherein the antioxidant is present in the pharmaceutical composition.

Claim 146. (Previously presented) The method according to claim 24, wherein the minoxidil or the pharmaceutically acceptable minoxidil salt is present in an amount of from 7.5 to 12% by weight, based on the total weight of the pharmaceutical composition.

Claim 147. (Previously presented) The method according to claim 21, wherein the acid is acetic acid or lactic acid.

Claim 148. (Previously presented) The method according to claim 147, wherein the acid is lactic acid.

Claim 149. (Previously presented) The method according to claim 21, wherein the water is present in an amount no greater than approximately 60% by weight based on the total weight of the composition.

Claim 150. (Previously presented) The method according to claim 21, wherein the cosolvent is an alkylene glycol.

Claim 151. (Previously presented) The method according to claim 150, wherein the alkylene glycol is selected from one or more of the group consisting of glycerol, 1,3-butylene glycol and propylene glycol.

Claim 152. (Previously presented) The method according to claim 151, wherein the alkylene glycol is glycerol.

Claim 153. (Previously presented) The method according to claim 21, wherein the acid is present at a level that provides at least 0.01 Normal acid.

Claim 154. (Previously presented) The method according to claim 21, wherein the acid is present in an amount equal to or greater than the amount of the minoxidil in Normal amounts.

Claim 155. (Previously presented) The method according to claim 21, wherein the lower alcohol is ethanol

Claim 156. (Previously presented) The method according to claim 155, wherein the

ratio of water to ethanol is approximately 1:1 to 1:3 by volume.

Claim 157. (Previously presented) The method according to claim 21, wherein the

higher alcohol is present in the pharmaceutical composition and is selected from the

group consisting of cetyl alcohol, stearyl alcohol, and combinations thereof.

Claim 158. (Previously presented) The method according to claim 21, wherein the

stabilizer is present in the pharmaceutical composition and is Polysorbate 60.

Claim 159. (Previously presented) The method according to claim 21, wherein the

propellant is selected from the group consisting of one or more hydrocarbons, dimethyl $\,$

ether, and a chlorofluorocarbon.

Claim 160. (Previously presented) The method according to claim 159, wherein the

propellant is one or more hydrocarbons.

Claim 161. (Previously presented) The method according to claim 21, wherein the

antioxidant is present in the pharmaceutical composition.

Claim 162. (New) The pharmaceutical composition according to claim 1, wherein the

Application No. 09/673,872 Attorney Docket No. C7979U Page 12 of 22

composition is free of propylene glycol.

Claim 163. (New) The method according to claim 21, wherein the composition is free of propylene glycol.